Research Achievements
Hideaki Bujo| 2012 | 2011 | 2010 | 2009 | 2008 |
| Papers| International Conferences |
Papers
Kuroda M‚ Bujo H‚ Aso M‚ Saito Y. Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases.
J. Diabet. Invest. 2011; 2 (5): 333-340
Asada A.‚ Kuroda M.‚ Aoyagi Y.‚ Bujo H.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Ishii I.‚ Aso M.‚ and Saito Y. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro.
Mol. Genet. Metab. 2011; 102 (2): 229-231
Kuroda M.‚ Aoyagi Y.‚ Asada S.‚ Bujo H.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Ishii I.‚ Machida K.‚ Matsumoto F.‚ Satoh K.‚ Aso M.‚ and Saito Y. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency.
The Open Gene Ther. J. 2011; 4 1-10
Nakata Z.‚ Nagae M.‚ Yasui N.‚ Bujo H.‚ Nogi T.‚ and Takagi J. Crystallization and preliminary crystallographic analysis of human LR11 Vps10p domain.
Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 2011; 67 (Pt1): 129-132
Asada S.‚ Kuroda M.‚ Aoyagi Y.‚ Fukaya Y.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Aso M.‚ Okamoto Y.‚ Nakayama T.‚ Saito Y.‚ and Bujo H. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy.
Am. J. Physiol. Cell Physiol. 2011; 301 (1): C181-185
International Conferences
Kuroda M.‚ Asada S‚ Aoyagi Y.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Aso M.‚ Saito Y.‚ and Bujo H. "Proliferative Adipocytes as Therapeutic Gene Vehicle toward Sustained Protein Replacement Therapy "
American Society of Gene & Cell Therapy 14th annual meeting 2011-6-23 Seattle/USA
Bujo H Circulating soluble LR11 -a novel molecule representing pathological immature cells-
Berlin Max-Delbrück-Center for Molecular Medicine symposium 2011-6-14 Berlin/Germany
Bujo H Circulating soluble LR11 -a novel molecule representing pathological immature cells-
Medical University of Vienna Biocenter Symposium 2011-6-13 Vienna/Austria
Bujo H Pharmacologic treatment for PAD in Japan – Cilostazol‚ and expected effects of lipid lowering drugs and probucol
1st Joint APSAVD-PLAS-PSVM Athersclerotic Prophrral Arterial Disease Forum 2011-5-22 Manila/Phillipine
Shimizu‚ N.‚ Nakaseko‚ C.‚ Takeuchi‚ M.‚ Ohwada‚ C.‚ Nishii‚ K.‚ Jiang‚ M.‚ Fukamachi‚ I. and Bujo‚ H. Soluble LR11‚ a modulator of G-CSF-mediated migration of HL-60 cells‚ is a potential circulating marker indicating the G-CSF-induced mobilization of hematopoietic stem cells.
Keystone Smmposia - Stem cells‚ cancer and metastasis- 2011-3-4 Kestone/USA
Bujo‚ H. LR11‚ a novel biomarker for cardiovascular diseases
Amsterdam University Academic Medical Center (AMC) Vascular Medicine Symposium 2011-3-2 Amsterdam/Hol£ģand
Shimizu N‚ Nakaseko C‚ Takeuchi M‚ Ohwada C‚ Tsukamoto S‚ Kawaguchi T‚ Nishii K‚ Jiang M‚ Yokote K‚ Fukamachi I‚ Bujo H Soluble LR11/SorLA‚ a potential circulating marker indicating the G-CSF-induced mobilization of hematopoietic stem cells‚ is a modulator of G-CDF-mediated migtration of HL-60 cells
The 53th American Society of Hematology 2011-12-9 San Diego/USA
Kawaguchi T‚ Ohwada C‚ Higashi M‚ Takeuchi M‚ Sakai S‚ Takeda Y‚ Shimizu N‚ Sakaida E‚ Takubo K‚ Ebinuma H‚ Fukamachi I‚ Tamaru J‚ Yokote K‚ Bujo H‚ Nakaseko C Serum soluble LR11 as a novel biomarker for B cell lymphoma
The 53th American Society of Hematology 2011-12-9 San Diego/USA
